SCHEMBL6549175

SCHEMBL6549175

ClC(Cl)=CCOc1cc(Cl)c(OCCCON=Cc2ccc(Cl)cc2)c(Cl)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.41
MAPT P10636 5/20 0.41
MEN1 O00255 3/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
TDP1 Q9NUW8 1/20 0.41
MAPK1 P28482 2/20 0.34
MAOB P27338 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.32
ALDH1A1 P00352 2/20 0.31
GAA P10253 1/20 0.31
PPARA Q07869 3/20 0.31
PPARG P37231 2/20 0.31
UBE2N P61088 2/20 0.31
NPSR1 Q6W5P4 2/20 0.31
LMNA P02545 2/20 0.31
KDM4E B2RXH2 1/20 0.31
NPC1 O15118 1/20 0.31
RAB9A P51151 1/20 0.31
CCR6 P51684 1/20 0.31
HTT P42858 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6549171 1.00 KMT2A (0.41) KMT2AMAPTMEN1L3MBTL1TDP1
SCHEMBL6548303 0.98 KMT2A (0.41) KMT2AMAPTMEN1L3MBTL1TDP1
SCHEMBL6548297 0.98 KMT2A (0.41) KMT2AMAPTMEN1L3MBTL1TDP1
SCHEMBL6548824 0.97 KMT2A (0.41) KMT2AMAPTMEN1L3MBTL1TDP1
SCHEMBL6548830 0.97 KMT2A (0.41) KMT2AMAPTMEN1L3MBTL1TDP1
SCHEMBL6549155 0.93 MAPT (0.38) KMT2AMAPTMEN1L3MBTL1TDP1
SCHEMBL6549160 0.93 MAPT (0.38) KMT2AMAPTMEN1L3MBTL1TDP1
SCHEMBL6548571 0.91 UNG (0.37) KMT2AMAPTMEN1L3MBTL1TDP1
SCHEMBL6548576 0.91 UNG (0.37) KMT2AMAPTMEN1L3MBTL1TDP1
SCHEMBL6549543 0.91 MAPT (0.38) KMT2AMAPTMEN1L3MBTL1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0975586-B1 OXIME COMPOUNDS, THEIR USE, AND INTERMEDIATES FOR THEIR PRODUCTION SUMITOMO CHEMICAL CO (JP) 2004-12-01 EP disclosed
US-6448444-B2 INSECTICIDES, MITICIDES SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2002-09-10 US disclosed
US-6437184-B1 INSECTICIDES, ACARICIDES SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2002-08-20 US disclosed
US-20020019569-A1 Oxime compounds, their use, and intermediates for their production SUMITOMO CHEMICAL COMPANY, LIMITED 2002-02-14 US disclosed
EP-0975586-A2 OXIME COMPOUNDS, THEIR USE, AND INTERMEDIATES FOR THEIR PRODUCTION Sumitomo Chemical Company, Limited (JP) 2000-02-02 EP disclosed
WO-1998045254-A2 OXIME COMPOUNDS, THEIR USE, AND INTERMEDIATES FOR THEIR PRODUCTION SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1998-10-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019569-A1 Oxime compounds, their use, and intermediates for their production CBR3, CBR1, NOX3 KMT2A 2985/4885MAPT 4623/4885MEN1 4425/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.